Enfusion, Inc. (NYSE:ENFN) CEO Oleg Movchan Sells 2,790 Shares

Enfusion, Inc. (NYSE:ENFN) CEO Oleg Movchan sold 2,790 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $11.48, for a total value of $32,029.20. Following the completion of the sale, the chief executive officer now directly owns 643,299 shares of the company’s stock, valued at approximately $7,385,072.52. This represents a 0.43 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Oleg Movchan also recently made the following trade(s):

• On Tuesday, January 7th, Oleg Movchan sold 2,771 shares of Enfusion stock. The stock was sold at an average price of $10.13, for a total value of $28,070.23.

Enfusion Stock Up 0.4 %

Shares of Enfusion stock opened at $11.45 on Thursday. The business has a 50 day moving average of $10.95 and a 200 day moving average of $9.85. The company has a market cap of $1.47 billion, a PE ratio of 286.20, a P/E/G ratio of 1.85 and a beta of 0.96. Enfusion, Inc. has a 52 week low of $7.83 and a 52 week high of $11.80.

Enfusion (NYSE:ENFN) last posted its quarterly earnings data on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The firm had revenue of $52.94 million during the quarter, compared to the consensus estimate of $53.98 million. Enfusion had a return on equity of 6.67% and a net margin of 1.70%. On average, research analysts anticipate that Enfusion, Inc. will post 0.06 earnings per share for the current year.

Hedge Funds Weigh In On Enfusion

Large investors have recently modified their holdings of the stock. KLP Kapitalforvaltning AS bought a new stake in Enfusion during the 4th quarter valued at about $75,000. Millennium Management LLC purchased a new stake in shares of Enfusion during the fourth quarter valued at approximately $114,000. Harbor Capital Advisors Inc. increased its position in shares of Enfusion by 12.4% during the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after acquiring an additional 1,315 shares in the last quarter. Belvedere Trading LLC purchased a new stake in Enfusion during the 3rd quarter valued at $114,000. Finally, Dark Forest Capital Management LP bought a new stake in shares of Enfusion in the 4th quarter worth $128,000. Hedge funds and other institutional investors own 81.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. William Blair reissued a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th. Stifel Nicolaus increased their price objective on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Finally, Piper Sandler increased their price objective on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research note on Monday, December 23rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Enfusion currently has a consensus rating of “Hold” and a consensus target price of $11.13.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.